BHV3000-311: Phase 3, Multicenter, Randomized, Double-Blind, Group Sequential, Placebo-Controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents # 6 to <18 Years of Age

Grants and Contracts Details

StatusActive
Effective start/end date3/19/213/28/24

Funding

  • Syneos Health LLC: $25,239.00